Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?

ABSTRACT: Acute and chronic liver disease are associated with substantial alterations in the hemostatic system. Evidence from both experimental and clinical studies suggests that anticoagulants slow the progression of liver disease. Efficacy of those anticoagulant drugs is, in part, attributed to a reduction of microthrombi formation within the liver. Although anticoagulant drugs show promising results, bleeding risk associated with these drugs is an obvious drawback, particularly in patients with a complex coagulopathy driven by decreased liver function. Identifying therapies that reduce intrahepatic thrombosis with minimal bleeding risk would significantly advance the field. Among the hemostatic alterations observed in patients are substantially increased levels of the platelet-adhesive protein vo

SUBMITTER: Groeneveld DJ 

PROVIDER: S-EPMC8582603 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature